Masahiro Morise1,2, Tomoyuki Hishida3, Akiko Takahashi1, Junji Yoshida4, Yuichiro Ohe1,5, Kanji Nagai4, Genichiro Ishii2. 1. Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. 2. Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Japan. 3. Department of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. thishida@east.ncc.go.jp. 4. Department of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. 5. Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Abstract
PURPOSE: This study aimed to evaluate the clinicopathological significance of cancer stem-like cell (CSLC) markers in high-grade neuroendocrine carcinoma (HGNEC) of the lung, including small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC). METHODS: We retrospectively studied patients who underwent surgical resection of SCLC (n = 60) and LCNEC (n = 45) to analyze their clinicopathological profiles and the immunohistochemical expression of putative CSLC markers (Caveolin, Notch, CD44, CD166, SOX2, ALDH1, and Musashi1). Staining scores for these markers in tumor cells were calculated by multiplying the percentage of positive tumor cells per lesion by the staining intensity level (0, 1, and 2); a score of ≥ 10 represented positive expression. RESULTS: There was a difference between SCLC and LCNEC with respect to both SOX2 (55 vs. 27 %, p = 0.003) and CD166 (27 vs. 47 %, p = 0.034) expression. ALDH1 expression was equally observed in SCLC and LCNEC (67 vs. 73 %, p = 0.46), and patients with ALDH1-positive HGNEC had significantly worse recurrence-free survival (RFS) and overall survival (OS) rates than those with ALDH1-negative HGNEC (5-year RFS: 39 vs. 67 %, p = 0.009; 5-year OS: 50 vs. 79 %, p = 0.021). A multivariate analysis revealed that positive ALDH1 expression was an independent unfavorable prognostic factor with respect to both RFS and OS. CONCLUSIONS: The differences in the expression profiles of CSLC markers might reflect morphological differences between SCLC and LCNEC. Positive ALDH1 expression in lung HGNEC was associated with an unfavorable patient prognosis, which suggested that ALDH1-positive tumor cells might be future therapeutic targets for the treatment of lung HGNEC.
PURPOSE: This study aimed to evaluate the clinicopathological significance of cancer stem-like cell (CSLC) markers in high-grade neuroendocrine carcinoma (HGNEC) of the lung, including small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC). METHODS: We retrospectively studied patients who underwent surgical resection of SCLC (n = 60) and LCNEC (n = 45) to analyze their clinicopathological profiles and the immunohistochemical expression of putative CSLC markers (Caveolin, Notch, CD44, CD166, SOX2, ALDH1, and Musashi1). Staining scores for these markers in tumor cells were calculated by multiplying the percentage of positive tumor cells per lesion by the staining intensity level (0, 1, and 2); a score of ≥ 10 represented positive expression. RESULTS: There was a difference between SCLC and LCNEC with respect to both SOX2 (55 vs. 27 %, p = 0.003) and CD166 (27 vs. 47 %, p = 0.034) expression. ALDH1 expression was equally observed in SCLC and LCNEC (67 vs. 73 %, p = 0.46), and patients with ALDH1-positive HGNEC had significantly worse recurrence-free survival (RFS) and overall survival (OS) rates than those with ALDH1-negative HGNEC (5-year RFS: 39 vs. 67 %, p = 0.009; 5-year OS: 50 vs. 79 %, p = 0.021). A multivariate analysis revealed that positive ALDH1 expression was an independent unfavorable prognostic factor with respect to both RFS and OS. CONCLUSIONS: The differences in the expression profiles of CSLC markers might reflect morphological differences between SCLC and LCNEC. Positive ALDH1 expression in lung HGNEC was associated with an unfavorable patient prognosis, which suggested that ALDH1-positive tumor cells might be future therapeutic targets for the treatment of lung HGNEC.
Entities:
Keywords:
Aldehyde dehydrogenase 1 (ALDH1); Cancer stem-like cells; High-grade neuroendocrine carcinoma; Large cell neuroendocrine carcinoma; Small cell lung carcinoma
Authors: Carmen Visus; Yangyang Wang; Antonio Lozano-Leon; Robert L Ferris; Susan Silver; Miroslaw J Szczepanski; Randall E Brand; Cristina R Ferrone; Theresa L Whiteside; Soldano Ferrone; Albert B DeLeo; Xinhui Wang Journal: Clin Cancer Res Date: 2011-08-19 Impact factor: 12.531
Authors: Tian Liao; Andreas M Kaufmann; Xu Qian; Voramon Sangvatanakul; Chao Chen; Tina Kube; Guoyou Zhang; Andreas E Albers Journal: J Cancer Res Clin Oncol Date: 2012-09-23 Impact factor: 4.553
Authors: Emina H Huang; Mark J Hynes; Tao Zhang; Christophe Ginestier; Gabriela Dontu; Henry Appelman; Jeremy Z Fields; Max S Wicha; Bruce M Boman Journal: Cancer Res Date: 2009-03-31 Impact factor: 12.701
Authors: Elaine Lai-Han Leung; Ronald R Fiscus; James W Tung; Vicky Pui-Chi Tin; Lik Cheung Cheng; Alan Dart-Loon Sihoe; Louis M Fink; Yupo Ma; Maria Pik Wong Journal: PLoS One Date: 2010-11-19 Impact factor: 3.240
Authors: Shuyan Liu; Chengfei Liu; Xiaoyun Min; Yuanyuan Ji; Na Wang; Dan Liu; Jiangyi Cai; Ke Li Journal: PLoS One Date: 2013-11-25 Impact factor: 3.240
Authors: Daniel Brungs; Elahe Minaei; Ann-Katrin Piper; Jay Perry; Ashleigh Splitt; Martin Carolan; Shantay Ryan; Xiao Juan Wu; Stéphanie Corde; Moeava Tehei; Morteza Aghmesheh; Kara L Vine; Therese M Becker; Marie Ranson Journal: Sci Rep Date: 2020-01-17 Impact factor: 4.379